Methotrexate revisited: effects of long‐term treatment in psoriasis

British Journal of Dermatology

Volumn 130, Issue 2, 1994, Pages 204-210

  VAN DOOREN GREEBE R J ^a   KUIJPERS, A L A ^a   MULDER, J ^a   DE BOO, TH ^a   VAN DE KERKHOF, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; STOMACH DISEASE; VERTIGO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; TIME FACTORS;

EID: 0028332968     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1994.tb02901.x     Document Type: Article

References (41)

1. Methotrexate
2. Methotrexate
3. Commentary: three decades of folic acid antagonists in dermatology
4. Methotrexate treatment of psoriatic arthritis
5. Benefits and adverse drug experiences during long‐term methotrexate treatment of 248 psoriatics
6. Effect of ‘aminopterin’ on epithelial tissues
7. Treatment of psoriasis with folic acid antagonists
8. Methotrexatc for psoriasis: a new therapeutic schedule
9. Psoriasis—liver—methotrexate interactions
10. Liver biopsies from psoriallcs related to metholrexate therapy. 3. Findings in post‐methotrexate liver biopsies from 160 patients
11. Methotrexatc induced liver cirrhosis. Studies including serial liver biopsies during continued treatment
12. Methotrexate maintenance therapy and liver damage in psoriasis
13. Effects of methotrexate on the liver in psoriasis
14. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis
15. Methotrexate maintenance following Ingram therapy in ‘difficult’ psoriasis
16. Methotrexate in psoriasis. Revised guidelines
17. Non‐parametric estimation from incomplete observations
18. Methotrexate the conservative treatment for psoriasis
19. Acitretin in psoriasis: an update
20. Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience
21. Methotrexate side‐effects
22. Psoriasis therapy and the risk of skin cancers
23. Methotrexate used for psoriasis and the risk of non‐cutaneous or cutaneous malignancy
24. Frequency of malignant neoplasms in 248 long‐term methotrexate‐treated psoriatics
25. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotrexate therapy in 88 patients
26. A cooperative prospective study of the effects of chemotherapy of psoriasis on liver biopsies
27. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate
28. Liver biopsy in methotrexate‐treated psoriatics—a re‐evaluation
29. Methotrexate hepatotoxicity In psoriasis
30. Methotrexate hepatotoxicity in psoriatic patients submitted to long‐term therapy
31. Methotrexate‐induced liver cirrhosis. A follow‐up
32. Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
33. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis
34. Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage
35. Ultrasound as a screening procedure for methotrexate‐induced hepatic damage in severe psoriasis
36. Ultrasound scanning in the detection of hepatic fibrosis and steatosis
37. A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long‐term methotrexate therapy
38. Ultrasound and radionuclide scans—poor indicators of liver damage in patients treated with methotrexate
39. Liver biopsies v liver scans in methotrexate‐treated patients with psoriasis
40. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate‐induced hepatotoxicity
41. The impact of methotrexate on psycho‐organic functioning